Apellis Receives FDA Approval for SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
Penn spinout Apellis Pharmaceuticals, Inc. received U.S. Food and Drug Administration (FDA) approval for their drug SYFOVRE™ (pegcetacoplan injection).
Penn Spinout ŌNŌCOR and B. Braun sign distribution agreement for ŌNŌ retrieval device
Onocor, a company formed through the UPstart program, has entered into an Amended and Restated License Agreement (ARLA) with Penn to expand its existing license to the ONO medical device.
Katalin Karikó and Drew Weissman Receive the 2022 Breakthrough Prize Award at Global Ceremony
Katalin Karikó and Drew Weissman received the 2022 Breakthrough Prize Award at a global ceremony hosted by television host James Corden.
Katalin Karikó Recognized in “Faces of American Innovation” Report Celebrating People Behind Life-Changing Inventions Fostered by the Bayh-Dole Act
Katalin Karikó, PhD, Adjunct Professor of Neurosurgery, was profiled in “Faces of American Innovation,” a report fostered by the Bayh-Dole Act that celebrates the people behind life-changing invention
Good Morning America features story of Emily Whitehead, the first pediatric patient to receive CAR T cell therapy
After receiving CAR T-cell treatment for leukemia in 2012, Emily is now 11 years cancer free, and is heading off to college this fall.
Verismo Therapeutics raises funding and expands partnership with Penn Medicine
Penn spinout company Verismo Therapeutics has successfully raised $7 million in a pre-Series A round led by BRV Capital Management.
6 Million NIH Grant Funds New Penn Medicine Research on Cardiac Cell Development
The Penn research team, led by principal investigator Dr. Rajan Jain aims to study how cardiac cells establish and maintain their identity over a lifetime.
New Approaches to CAR-T Therapy
The FDA first approved of chimeric antigen receptor (CAR) T cell therapy in 2017, and Penn Medicine has since been dedicated to finding further applications to the treatment.
Future mRNA Vaccine Applications Highlighted
The New York Post recently published an article discussing future applications of mRNA, including vaccinations against tuberculosis, malaria, high cholesterol, HIV, and more.
4D Molecular Therapeutics (4DMT) Acquires Rights to Penn Medicine Invented Technology from Aevitas Therapeutics
Penn spinout Aevitas Therapeutics recently executed an asset purchase agreement with California-based biotechnology company 4D Molecular Therapeutics (4DMT).